Evgeny Berdyshev1, Elena Goleva2, Irina Bronova1, Anna Sofia Bronoff2, Joanne E Streib2, Kathryn A Vang2, Brittany N Richers2, Patricia Taylor2, Lisa Beck3, Miguel Villarreal4, Keli Johnson4, Gloria David4, Mark K Slifka5, Jon Hanifin6, Donald Y M Leung7. 1. Division of Pulmonary, Critical Care and Sleep Medicine, National Jewish Health, Denver, Colo. 2. Department of Pediatrics, National Jewish Health, Denver, Colo. 3. Department of Dermatology, Medicine and Pathology, University of Rochester Medical Center, Rochester, NY. 4. Rho Federal Systems Division, Inc, Durham, NC. 5. Oregon National Primate Research Center, Oregon Health and Science University, Beaverton, Ore. 6. Department of Dermatology, Oregon Health and Science University, Portland, Ore. 7. Department of Pediatrics, National Jewish Health, Denver, Colo. Electronic address: leungd@njhealth.org.
Abstract
BACKGROUND: Life-threatening viral diseases such as eczema herpeticum (EH) and eczema vaccinatum (EV) occur in <5% of individuals with atopic dermatitis (AD). The diagnosis of AD, however, excludes all individuals with AD from smallpox vaccination. OBJECTIVES: We sought to identify circulatory and skin lipid biomarkers associated with EH and EV. METHODS: Stratum corneum and plasma samples from 15 subjects with AD and a history of EH, 13 age- and gender-matched subjects with AD and without EH history, and 13 healthy nonatopic (NA) controls were analyzed by liquid chromatography tandem mass spectrometry for sphingolipid content. Sphingosine-1-phosphate (S1P) and ceramide levels were validated in plasma samples from the Atopic Dermatitis Vaccinia Network/Atopic Dermatitis Research Network repository (12 NA, 12 AD, 23 EH) and plasma from 7 subjects with EV and 7 matched subjects with AD. S1P lyase was downregulated in human primary keratinocytes to evaluate its effect on herpes simplex virus 1 (HSV-1) replication in vitro. RESULTS: The stratum corneum of patients with EH demonstrated significantly higher levels of free sphingoid bases than those in patients who were NA, indicating enhanced sphingolipid turnover in keratinocytes (P < .05). Plasma from 2 independent cohorts of patients with EH had a significantly increased S1P/ceramide ratio in subjects with EH versus those with AD and or who were NA (P < .01). The S1P level in plasma from subjects with EV was twice the level in plasma from subjects with AD (mean = 1,533 vs 732 pmol/mL; P < .001). Downregulation of S1P lyase expression with silencing RNA led to an increased S1P level and doubled HSV-1 titer in keratinocytes. CONCLUSIONS: Our data point to long-term abnormalities in the S1P signaling system as a biomarker for previous disseminated viral diseases and a potential treatment target in recurring infections.
BACKGROUND: Life-threatening viral diseases such as eczema herpeticum (EH) and eczema vaccinatum (EV) occur in <5% of individuals with atopic dermatitis (AD). The diagnosis of AD, however, excludes all individuals with AD from smallpox vaccination. OBJECTIVES: We sought to identify circulatory and skin lipid biomarkers associated with EH and EV. METHODS: Stratum corneum and plasma samples from 15 subjects with AD and a history of EH, 13 age- and gender-matched subjects with AD and without EH history, and 13 healthy nonatopic (NA) controls were analyzed by liquid chromatography tandem mass spectrometry for sphingolipid content. Sphingosine-1-phosphate (S1P) and ceramide levels were validated in plasma samples from the Atopic Dermatitis Vaccinia Network/Atopic Dermatitis Research Network repository (12 NA, 12 AD, 23 EH) and plasma from 7 subjects with EV and 7 matched subjects with AD. S1P lyase was downregulated in human primary keratinocytes to evaluate its effect on herpes simplex virus 1 (HSV-1) replication in vitro. RESULTS: The stratum corneum of patients with EH demonstrated significantly higher levels of free sphingoid bases than those in patients who were NA, indicating enhanced sphingolipid turnover in keratinocytes (P < .05). Plasma from 2 independent cohorts of patients with EH had a significantly increased S1P/ceramide ratio in subjects with EH versus those with AD and or who were NA (P < .01). The S1P level in plasma from subjects with EV was twice the level in plasma from subjects with AD (mean = 1,533 vs 732 pmol/mL; P < .001). Downregulation of S1P lyase expression with silencing RNA led to an increased S1P level and doubled HSV-1 titer in keratinocytes. CONCLUSIONS: Our data point to long-term abnormalities in the S1P signaling system as a biomarker for previous disseminated viral diseases and a potential treatment target in recurring infections.
Authors: Takashi Sakai; Nadine Herrmann; Laura Maintz; Tim Joachim Nümm; Thomas Welchowski; Ralf A Claus; Markus H Gräler; Thomas Bieber Journal: Allergy Date: 2021-04-07 Impact factor: 13.146
Authors: Samar M Hammad; Jason S Pierce; Farzan Soodavar; Kent J Smith; Mohammed M Al Gadban; Barbara Rembiesa; Richard L Klein; Yusuf A Hannun; Jacek Bielawski; Alicja Bielawska Journal: J Lipid Res Date: 2010-07-21 Impact factor: 5.922
Authors: Lisa A Beck; Mark Boguniewicz; Tissa Hata; Lynda C Schneider; Jon Hanifin; Rich Gallo; Amy S Paller; Susi Lieff; Jamie Reese; Daniel Zaccaro; Henry Milgrom; Kathleen C Barnes; Donald Y M Leung Journal: J Allergy Clin Immunol Date: 2009-06-27 Impact factor: 10.793